Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 6/20 | 0.49 |
| ▸ | MMP9 | P14780 | 5/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27396675 | 0.87 | BACE1 (0.60) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL6896602 | 0.86 | BACE1 (0.59) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL6772869 | 0.85 | MMP2 (0.67) | POLBMMP2MMP9ADAMTS4MEN1 | |
| SCHEMBL7189021 | 0.83 | POLB (0.57) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL3837363 | 0.83 | BACE1 (0.54) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL7194146 | 0.82 | MMP2 (0.53) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL3924475 | 0.81 | BACE1 (0.73) | BACE1POLBCTSLCTSSMMP2 | |
| SCHEMBL3927017 | 0.81 | BACE1 (0.76) | BACE1POLB | |
| SCHEMBL3924110 | 0.81 | BACE1 (0.66) | BACE1MMP2MMP9MAPT | |
| SCHEMBL7754801 | 0.81 | BACE1 (0.66) | BACE1MMP2MMP9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | BACE1 2027/4885POLB 4505/4885CTSL 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.